Clinical manifestations and outcome of XXXX .

@entity1 @entity267 @entity1036 @entity230 @entity378 @entity3170
AIM: To study the clinical manifestations and outcome of @entity1 with @entity378 treated with antituberculous therapy without concomitant use of systemic @entity230 . METHODS: We reviewed retrospectively the medical records of eight consecutive @entity1 with @entity378 . @entity1 were treated unsuccessfully with topical and/or systemic @entity230 . They underwent complete ophthalmic examination, systemic evaluation, laboratory investigations and imaging. Tuberculin skin test was done with purified protein derivative (PPD) on all @entity1 . The diagnosis of @entity378 was made based on clinical findings of @entity3170 with adjacent peripheral corneal @entity1036 , positive PPD test of 15   mm of induration or more, response to antituberculous treatment (ATT) within 4   weeks and exclusion of other causes of sclerokeratitis. Antituberculous drugs were given for a minimum of 6   months without concomitant use of corticosteroids. The outcome measure was resolution of the ocular surface inflammation of the sclera and @entity267 . RESULTS: Eight consecutive @entity1 with a diagnosis of @entity378 were included. There were one male and seven female @entity1 . The mean age was 29   years with an age range of 7-43   years. The involvement of the sclera was nodular in six @entity1 and diffuse in two. The involvement of the @entity267 consisted of peripheral corneal stromal inflammation adjacent to the area of @entity3170 . @entity1 responded to antituberculous medications with complete resolution of the sclerokeratitis without topical or systemic anti-inflammatory agents. CONCLUSIONS: Antituberculous medications can lead to complete resolution of the sclerokeratitis without concomitant use of @entity230 , or other anti-inflammatory agents.
